The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective
The emergence of immunotherapy, particularly programmed cell death 1 (PD-1) and programmed cell death ligand-1 (PD-L1) produced profound transformations for treating non-small cell lung cancer (NSCLC). Nevertheless, not all NSCLC patients can benefit from immunotherapy in clinical practice. In addit...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1249980/full |
| _version_ | 1797688847318908928 |
|---|---|
| author | Shuai Liang Hanyu Wang Haixia Tian Zhicheng Xu Min Wu Dong Hua Dong Hua Chengming Li |
| author_facet | Shuai Liang Hanyu Wang Haixia Tian Zhicheng Xu Min Wu Dong Hua Dong Hua Chengming Li |
| author_sort | Shuai Liang |
| collection | DOAJ |
| description | The emergence of immunotherapy, particularly programmed cell death 1 (PD-1) and programmed cell death ligand-1 (PD-L1) produced profound transformations for treating non-small cell lung cancer (NSCLC). Nevertheless, not all NSCLC patients can benefit from immunotherapy in clinical practice. In addition to limited response rates, exorbitant treatment costs, and the substantial threats involved with immune-related adverse events, the intricate interplay between long-term survival outcomes and early disease progression, including early immune hyperprogression, remains unclear. Consequently, there is an urgent imperative to identify robust predictive and prognostic biological markers, which not only possess the potential to accurately forecast the therapeutic efficacy of immunotherapy in NSCLC but also facilitate the identification of patient subgroups amenable to personalized treatment approaches. Furthermore, this advancement in patient stratification based on certain biological markers can also provide invaluable support for the management of immunotherapy in NSCLC patients. Hence, in this review, we comprehensively examine the current landscape of individual biological markers, including PD-L1 expression, tumor mutational burden, hematological biological markers, and gene mutations, while also exploring the potential of combined biological markers encompassing radiological and radiomic markers, as well as prediction models that have the potential to better predict responders to immunotherapy in NSCLC with an emphasis on some directions that warrant further investigation which can also deepen the understanding of clinicians and provide a reference for clinical practice. |
| first_indexed | 2024-03-12T01:37:31Z |
| format | Article |
| id | doaj.art-c00e77a15920400aa529e05af2e3fbe8 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-12T01:37:31Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-c00e77a15920400aa529e05af2e3fbe82023-09-11T05:39:14ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-09-011410.3389/fimmu.2023.12499801249980The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspectiveShuai Liang0Hanyu Wang1Haixia Tian2Zhicheng Xu3Min Wu4Dong Hua5Dong Hua6Chengming Li7Department of Oncology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, ChinaWuxi School of Medicine, Jiangnan University, Wuxi, ChinaDepartment of Oncology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, ChinaDepartment of Oncology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, ChinaSuzhou Cancer Center Core Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, ChinaDepartment of Oncology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, ChinaWuxi School of Medicine, Jiangnan University, Wuxi, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaThe emergence of immunotherapy, particularly programmed cell death 1 (PD-1) and programmed cell death ligand-1 (PD-L1) produced profound transformations for treating non-small cell lung cancer (NSCLC). Nevertheless, not all NSCLC patients can benefit from immunotherapy in clinical practice. In addition to limited response rates, exorbitant treatment costs, and the substantial threats involved with immune-related adverse events, the intricate interplay between long-term survival outcomes and early disease progression, including early immune hyperprogression, remains unclear. Consequently, there is an urgent imperative to identify robust predictive and prognostic biological markers, which not only possess the potential to accurately forecast the therapeutic efficacy of immunotherapy in NSCLC but also facilitate the identification of patient subgroups amenable to personalized treatment approaches. Furthermore, this advancement in patient stratification based on certain biological markers can also provide invaluable support for the management of immunotherapy in NSCLC patients. Hence, in this review, we comprehensively examine the current landscape of individual biological markers, including PD-L1 expression, tumor mutational burden, hematological biological markers, and gene mutations, while also exploring the potential of combined biological markers encompassing radiological and radiomic markers, as well as prediction models that have the potential to better predict responders to immunotherapy in NSCLC with an emphasis on some directions that warrant further investigation which can also deepen the understanding of clinicians and provide a reference for clinical practice.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1249980/fullnon-small cell lung cancer (NSCLC)immunotherapyprognostic biological markersanti-PD-(L)1review |
| spellingShingle | Shuai Liang Hanyu Wang Haixia Tian Zhicheng Xu Min Wu Dong Hua Dong Hua Chengming Li The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective Frontiers in Immunology non-small cell lung cancer (NSCLC) immunotherapy prognostic biological markers anti-PD-(L)1 review |
| title | The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective |
| title_full | The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective |
| title_fullStr | The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective |
| title_full_unstemmed | The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective |
| title_short | The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective |
| title_sort | prognostic biological markers of immunotherapy for non small cell lung cancer current landscape and future perspective |
| topic | non-small cell lung cancer (NSCLC) immunotherapy prognostic biological markers anti-PD-(L)1 review |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1249980/full |
| work_keys_str_mv | AT shuailiang theprognosticbiologicalmarkersofimmunotherapyfornonsmallcelllungcancercurrentlandscapeandfutureperspective AT hanyuwang theprognosticbiologicalmarkersofimmunotherapyfornonsmallcelllungcancercurrentlandscapeandfutureperspective AT haixiatian theprognosticbiologicalmarkersofimmunotherapyfornonsmallcelllungcancercurrentlandscapeandfutureperspective AT zhichengxu theprognosticbiologicalmarkersofimmunotherapyfornonsmallcelllungcancercurrentlandscapeandfutureperspective AT minwu theprognosticbiologicalmarkersofimmunotherapyfornonsmallcelllungcancercurrentlandscapeandfutureperspective AT donghua theprognosticbiologicalmarkersofimmunotherapyfornonsmallcelllungcancercurrentlandscapeandfutureperspective AT donghua theprognosticbiologicalmarkersofimmunotherapyfornonsmallcelllungcancercurrentlandscapeandfutureperspective AT chengmingli theprognosticbiologicalmarkersofimmunotherapyfornonsmallcelllungcancercurrentlandscapeandfutureperspective AT shuailiang prognosticbiologicalmarkersofimmunotherapyfornonsmallcelllungcancercurrentlandscapeandfutureperspective AT hanyuwang prognosticbiologicalmarkersofimmunotherapyfornonsmallcelllungcancercurrentlandscapeandfutureperspective AT haixiatian prognosticbiologicalmarkersofimmunotherapyfornonsmallcelllungcancercurrentlandscapeandfutureperspective AT zhichengxu prognosticbiologicalmarkersofimmunotherapyfornonsmallcelllungcancercurrentlandscapeandfutureperspective AT minwu prognosticbiologicalmarkersofimmunotherapyfornonsmallcelllungcancercurrentlandscapeandfutureperspective AT donghua prognosticbiologicalmarkersofimmunotherapyfornonsmallcelllungcancercurrentlandscapeandfutureperspective AT donghua prognosticbiologicalmarkersofimmunotherapyfornonsmallcelllungcancercurrentlandscapeandfutureperspective AT chengmingli prognosticbiologicalmarkersofimmunotherapyfornonsmallcelllungcancercurrentlandscapeandfutureperspective |